Ira Klein, MD, Discusses Quality Measures in Oncology

About Us

Publications

AJMC TV

Events

Conferences

News

Authors

Essentials

Research

ACO Coalition

TEVR2012

Ira Klein, MD, Discusses Quality Measures in Oncology

Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology. Dr. Klein says that measurement is a driver for value and healthcare in the future. Quality measures like QOPI and HEDIS allow oncologists to measure how they should be rewarded and recognized for making improvement.

This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.

More on AJMC.COM

Gilead's Idelalisib Receives CHMP Recommendation for Treating CLL and FL

The recommendation to the EMA came soon after Zydiga (idelalisib) was approved in the US.

Clinical Trial Will Evaluate Drug's Ability to Protect Normal Cells During Chemotherapy

The drug is to be administered right before chemotherapy or radiation, to bind to and inhibit cell division in normal cells and reduce the adverse effects of chemotherapy.

FDA Approves Imbruvica for Treating Chromosome 17-Deletion CLL Patients

New trial data confirms its use as standard therapy for CLL.

Study Reports Exclusion from Trials Responsible for Poor Outcomes in HIV-Positive Cancer Patients

HIV-positive individuals are not usually enrolled in clinical trials, resulting in a knowledge-gap on their treatment options.

AstraZeneca Investing in Blood Test to Personalize NSCLC Treatment

AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.

Innovative Approaches by Pharmacists Save Costs at a Comprehensive Cancer Center

Active implementation of cost-saving measures successfully cut down expenditure at the Norris Comprehensive Cancer Center.

BMS Announces Collaboration With Ono Pharmaceutical to Market Opdivo

Opdivo (Nivolumab) recently received regulatory approval in Japan for the treatment of patients with unresectable melanoma, the first global approval for a PD-1 inhibitor.